Category Archives: Myocardial Infarction

Myocardial Infarction Drugs Market analysis report has recently added by HealthCare Intelligence Markets which helps to make informed business decisions. This research report further identifies the market segmentation along with their sub-types. The Global Myocardial Infarction Drugs Market is expected to reach a huge CAGR during the forecast period. Continue reading →

Transparency Market Research (TMR) has published a new report titled, Anticoagulants Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026. According to the report, theglobal anticoagulants marketwas valued at US$ 21,759.3 Mn in 2018 and is projected to expand at a CAGR of 8.0% from 2018 to 2026. Continue reading →

The scope of the Report: The report analyzes the key opportunities, CAGR, and Y-o-Y growth rates to allow readers to understand all the qualitative and quantitative aspects of the Myocardial Infarction Drug market. Continue reading →

It provides the Myocardial Infarction Treatment industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). A recently published report Myocardial Infarction Treatment Market 2020 is a detailed analogy that gives readers insight into the complexity of various factors such as growth rates, technological advances and impacts of socio-economic conditions that affect the marketplace. Continue reading →

OBJECTIVES: To assess the impact of different types of anemia and of concomitant non-cardiovascular chronic illnesses on outcomes of patients with ST-segment elevationmyocardial infarction(STEMI) and baseline anemia admitted to the Intensive Cardiac Care Unit. Based on the mean corpuscular volume, anemia was stratified into: microcytic ( Continue reading →

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today it has received CE Mark approval to market and distribute its SuperSaturated Oxygen (SSO2) Therapy System in Europe. SSO2 Therapy provides interventional cardiologists with the first and only clinically proven treatment beyond percutaneous coronary intervention (PCI) to significantly reduce muscle damage in heart attack patients.1 SSO2 Therapy will support clinicians in delivering the highest quality of care for their STEMI patients in Europe and other countries that accept CE Mark, said Neil Johnston, President, ZOLL Circulation Continue reading →

With much of the medical world focusing on the COVID-19 crisis, two new studies on preeclampsia a pregnancy complication characterized by high blood pressure that can quickly progress to organ damage and even death drew relatively little attention. But those studies contain critically important findings relevant to women at all stages of pregnancy and for the clinicians who care for them. Continue reading →

Up-titration to high-intensity statins early on in the course of treatment was found to be associated with a lower risk for cardiovascular (CV) events compared with no up-titration in patients at very high risk for CV disease, according to a study published in the European Heart Journal Quality Care and Clinical Outcomes. The data of 192,435 patients (ages, 18 years; mean age, 68 years) from a Swedish national population-based registry database were retrospectively examined. Patients in this cohort were at very high risk for atherosclerotic CV disease according to European Society of Cardiology guideline definitions and had initiated moderate-intensity stating therapy between 2006 and 2013. Continue reading →

Dose-limiting toxicities (DLTs) were minimal with the combination of canakinumab plus pembrolizumab (Keytruda), and platinum-based doublet chemotherapy in patients with advanced or metastatic nonsmall cell lung cancer who were treated in the phase II CANOPY-1 study (NCT03631199), demonstrating that the combination could be well-tolerated in these patients.1 Results from the safety run-in portion of the study were presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting. The purpose for part 1 of the CANOPY-1 study was to determine a safe dose of canakinumab for the second portion of the study. Overall, 30 patients with previously untreated stage IIIB or IIIC or stage IV NSCLC were enrolled to the safety run-in portion of CANOPY-1 Continue reading →

BACKGROUND: ST-segment elevationmyocardial infarction(STEMI) remains a leading cause of morbidity and mortality around the world. In patients with STEMI undergoing primary percutaneous coronary intervention (PPCI), electrocardiographic measures of ST-segment resolution (STR) may give information about themyocardialperfusion and poor prognosis. To investigate the relation of endocan and galectin-3 levels with STR in STEMI patients Continue reading →